SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period a year earlier. The company also reported first-half revenue of $25.0 million, up 65.6% from $15.1 million in the first half of 2025. These results, released August 19, 2026, highlight the accelerating adoption of the company's SSi Mantra surgical robotic system.
The revenue growth was driven by a 30.4% increase in SSi Mantra installations during the quarter, reaching 30 systems. The installed base now stands at 224 systems across 12 countries, with a cumulative total of 12,272 surgeries performed using the platform. This expansion reflects growing confidence in the system's capabilities among healthcare providers, particularly in emerging markets where demand for minimally invasive surgery is rising.
Gross profit for the second quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-ago quarter. For the first half, gross profit rose 77.5% to $12.4 million, with gross margin improving to a level consistent with the company's growth strategy. The margin dip in Q2 may be attributed to increased investments in production capacity and regulatory processes.
A key focus for SS Innovations is expanding its regulatory footprint. The company is targeting U.S. FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. These milestones are critical catalysts that could open access to two of the world's largest medical device markets, significantly boosting commercial potential. According to the company, these regulatory achievements would enhance the SSi Mantra's credibility and competitiveness against established players like Intuitive Surgical's da Vinci system.
The company's telesurgery achievements are also extending the clinical profile of the SSi Mantra, demonstrating its ability to enable remote surgical procedures. This capability is particularly relevant in addressing healthcare access disparities in underserved regions. However, system installations remain the primary commercial growth driver, as each new installation generates recurring revenue from instruments and services.
The financial results were disclosed in a press release issued via NewMediaWire, with additional details available in the company's newsroom at https://ibn.fm/SSII. Investors should note that forward-looking statements in the release are subject to risks and uncertainties, as detailed in the company's SEC filings.
The strong performance underscores the growing demand for surgical robotics beyond traditional markets. As SS Innovations expands its global footprint and advances regulatory approvals, the company is well-positioned to capitalize on the increasing adoption of robotic-assisted surgery, which offers precision, reduced patient trauma, and faster recovery times. For industry observers, the company's trajectory signals a broader trend toward more accessible and affordable robotic surgical solutions, potentially reshaping competitive dynamics in the healthcare technology sector.
